IR@PKUHSC  > 北京大学药学院  > 药事管理与临床药学系
学科主题药学
Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis
Cui, J. Y.; Zhou, R. R.; Han, S.; Wang, T. S.; Wang, L. Q.; Xie, X. H.
通讯作者Xie, X. H.(1)
关键词fasting plasma glucose glycemic HbA1c network meta-analysis statin type 2 diabetes
刊名JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
2018-08-01
DOI10.1111/jcpt.12690
43期:4页:556-570
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pharmacology & Pharmacy
研究领域[WOS]Pharmacology & Pharmacy
关键词[WOS]SIMVASTATIN TREATMENT ; ENDOTHELIAL FUNCTION ; INSULIN-SECRETION ; MELLITUS PATIENTS ; ATORVASTATIN ; CHOLESTEROL ; PLACEBO ; RISK ; HYPERCHOLESTEROLEMIA ; INTERVENTIONS
英文摘要

What is known and objectiveStatins are the cornerstone of primary and secondary prevention of cardiovascular diseases (CVDs) and are effective for the prevention of vascular events in diabetic patients. Diabetes mellitus is an important risk factor for CVDs .The majority of patients with diabetes mellitus benefits from statin therapy. According to the recent clinical guidelines of the American College of Cardiology and the American Heart Association, moderate-intensity or high-intensity statin therapy should be used as the primary prevention for individuals with diabetes mellitus, aged between 40 and 75years and with low-density lipoprotein cholesterol (LDL-C) from 70 to 189mg/dL. The objective of this review was to compare the associations of individual statins with their adverse effects on glycemic control in patients with type 2 diabetes mellitus (T2DM).

MethodsMEDLINE, EMBASE and CENTRAL were searched from inception through March 2017. There were included randomized controlled trials comparing statins with placebo or active comparators in patients with T2DM. The endpoints of interest were glycated haemoglobin A1(C) (HbA1(C)) and fasting plasma glucose (FPG). We performed a pairwise meta-analysis and a network meta-analysis within a frequentist framework. The standard mean differences (SMD) and 95% confidence intervals (CI) were calculated.

ResultsTwenty-three trials were included. A significant increase in HbA1c was detected in the pairwise meta-analysis when statins as a class were compared with placebo (SMD: 0.11). Moderate-intensity pitavastatin lowered HbA1c compared with moderate-intensity atorvastatin (SMD: -0.16), high-intensity atorvastatin (SMD: -0.77), moderate-intensity rosuvastatin (SMD: -0.16) and low-intensity pravastatin (SMD: -0.15). Moderate-intensity simvastatin lowered HbA1c compared with high-intensity rosuvastatin (SMD: -0.45) and high-intensity atorvastatin (SMD: -0.77). High-intensity atorvastatin elevated HbA1c compared with placebo (SMD: 0.63), moderate-intensity rosuvastatin (SMD: 0.50), low-intensity pravastatin (SMD: 0.51) and moderate-intensity atorvastatin (SMD: 0.50). Moderate-intensity pitavastatin has lowered FPG compared with placebo (SMD: -0.55), moderate-intensity rosuvastatin (SMD: -0.65), moderate-intensity atorvastatin (SMD: -0.65) and high-intensity atorvastatin (SMD: -1.25). High-intensity atorvastatin has elevated FPG compared with placebo (SMD: 0.70), moderate-intensity atorvastatin (SMD: 0.60), moderate-intensity rosuvastatin (SMD: 0.60) and moderate-intensity simvastatin (SMD: 0.90).

What is new and conclusionStatins were associated with an increase in HbA1c compared with placebo. In patients with T2DM, moderate-intensity pitavastatin improved the glycemic control whereas high-intensity atorvastatin worsened it. Appropriate statins should be administered for patients with diabetes mellitus.

语种英语
WOS记录号WOS:000437685800016
通讯作者邮箱xxhrenee@bjmu.edu.cn
第一作者单位Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China
通讯作者单位Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China
ISSN0269-4727
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/142186
专题北京大学药学院_药事管理与临床药学系
北京大学临床肿瘤学院_日间化疗病区
作者单位Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Cui, J. Y.,Zhou, R. R.,Han, S.,et al. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis[J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS,2018,43(4):556-570.
APA Cui, J. Y.,Zhou, R. R.,Han, S.,Wang, T. S.,Wang, L. Q.,&Xie, X. H..(2018).Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS,43(4),556-570.
MLA Cui, J. Y.,et al."Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis".JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS 43.4(2018):556-570.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Cui, J. Y.]的文章
[Zhou, R. R.]的文章
[Han, S.]的文章
百度学术
百度学术中相似的文章
[Cui, J. Y.]的文章
[Zhou, R. R.]的文章
[Han, S.]的文章
必应学术
必应学术中相似的文章
[Cui, J. Y.]的文章
[Zhou, R. R.]的文章
[Han, S.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。